Exoxemis

Exoxemis is a private, clinical-stage biotech developing Zempia®, a novel topical antiseptic based on the enzyme Myeloperoxidase (MPO). Its platform is designed to kill a broad spectrum of pathogens, including antibiotic-resistant bacteria, while uniquely inactivating bacterial endotoxins to potentially prevent sepsis. The company has completed a Phase III safety trial but has not yet received FDA approval, positioning it as a pre-revenue entity with a significant but high-risk opportunity in wound care and infection prevention.

Topical biological antiseptic system based on purified Myeloperoxidase (MPO) enzyme. The platform generates antimicrobial oxidants (hypochlorous acid, singlet oxygen) to kill pathogens and uniquely inactivates bacterial endotoxins to prevent sepsis.

Zempia® competes in the topical antiseptic market dominated by established agents like silver, iodine, and chlorhexidine. Its key differentiator is the dual mechanism of killing pathogens and inactivating endotoxin, a claim not made by current competitors. However, it must demonstrate superior clinical efficacy and cost-effectiveness to displace these entrenched standards.